Altoida and Ionian University Investigate Breakthrough Software Device for Parkinson's Disease Diagnosis

Altoida, Inc. the worlds leading Precision Neurology company, announced a collaboration with the Bioinformatics and Human Electrophysiology Laboratory (BiHELab), Department of Informatics at Ionian University.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Monday, October 25, 2021
Information
Tags: 
Data Management, Other Science, Seniors, Technology, Research, Managed Care, Other Health, Consumer, Pharmaceutical, Mental Health, Genetics, Fitness & Nutrition, Clinical Trials, Biotechnology, Other Education, University, Software, Health, Education, Science, DBm, Diagnosis, Technology, LinkedIn, Neurodegeneration, Neuron, AR, Twitter, Ionian University, Partnership, Patient, FDA, TUM Department of Informatics, Bioinformatics, Parkinson's disease, Risk, Intelligence, Life, Smartphone, Biomarker, Health, Artificial intelligence, Therapy, Department, Medical device, Medical imaging
Geotags: 
Europe, United States, Greece
⚠ generated by AI ↴
Organisation: 
ALTOIDA, INC.
Summary
Key Points: 
  • Altoida, Inc. the worlds leading Precision Neurology company, announced a collaboration with the Bioinformatics and Human Electrophysiology Laboratory (BiHELab), Department of Informatics at Ionian University.
  • The collaboration will investigate Altoidas medical device, an FDA Breakthrough Device being developed for early diagnosis and monitoring of Alzheimers disease, for early diagnosis and prediction of Parkinsons disease onset.
  • In that time, Altoida and BiHELab will apply and Altoidas technology to analysis of Parkinsons disease progression and evaluate its efficacy in diagnosing Parkinsons in the preclinical phase.
  • For Parkinsons patients, accurate prediction and early diagnosis could enable intervention before the extensive damage of dopaminergic neurons occurs."


Altoida, Inc. the world’s leading Precision Neurology company, announced a collaboration with the Bioinformatics and Human Electrophysiology Laboratory (BiHELab), Department of Informatics at Ionian University. The collaboration will investigate Altoida’s medical device, an FDA Breakthrough Device being developed for early diagnosis and monitoring of Alzheimer’s disease, for early diagnosis and prediction of Parkinson’s disease onset.

The three-year collaboration will kick off with the launch of the Digital Innovation HUB: Health Hub, a public-private partnership with 25 participating entities dedicated to fostering healthcare research and innovation in Greece. In that time, Altoida and BiHELab will apply and Altoida’s technology to analysis of Parkinson’s disease progression and evaluate its efficacy in diagnosing Parkinson’s in the preclinical phase.

With a 10-minute series of augmented reality and digital motor activities that simulate complex activities of daily living, Altoida transforms any smartphone or tablet into the world’s most powerful medical device to assess neurocognitive function. The company won Breakthrough Designation for development of their device to use artificial intelligence to help predict conversion to Alzheimer’s, and they secured funding from the Alzheimer’s Drug Discovery Foundation Diagnostics Accelerator to test their device for diagnosis in the preclinical phase of Alzheimer’s.

"This is recognition of the strong clinical need for early diagnosis of Parkinson's disease, which could enable preventive and therapeutic intervention in the early stages to delay onset and improve clinical outcomes," said Ioannis Tarnanas, Ph.D., Chief Scientific Officer of Altoida. “We are excited to collaborate with BiHELab to further develop our technology, and to engage with the Health Hub’s scientific network to bring this application to life for the Greek population.”

BiHELab is a leading research center specializing in the application of mathematical modeling and machine learning techniques to neurodegenerative diseases, like Parkinson’s and Alzheimer’s.

"By applying innovative bioinformatics and machine learning techniques to clinical data, BiHeLab has aimed to identify novel biomarkers that are most indicative of risk of Parkinson’s disease,” said Professor Panagiotis Vlamos, Scientific Director at BiHELab. “For Parkinson’s patients, accurate prediction and early diagnosis could enable intervention before the extensive damage of dopaminergic neurons occurs."

Altoida’s device is a Computerized Cognitive Assessment Aid that is classified as Class II, 510(k) exempt.

About Altoida, Inc.

Altoida, Inc is creating a new gold standard in brain health with Precision Neurology. Our innovative approach combines novel digital biomarkers (dBM) with immersive augmented reality (AR) and powerful artificial intelligence (AI). The result is our validated device and platform built on more than twenty years of cutting-edge scientific research. Our products are backed by peer-reviewed publications and multinational clinical trials, and are built by our expert team of scientists, clinicians and engineers. Altoida, Inc. is funded by M-Ventures, Eisai Innovation, Hikma Ventures, GreySky Venture Partners, FYRFLY, Alpana Ventures and VI Partners. For more on Altoida, please visit www.altoida.com and connect with us on LinkedIn and Twitter.

Copyright: 
Copyright Business Wire 2021